The antigen cross-presentation of tumor-infiltrating DCs in YTHDF1-deficient melanoma or colon cancers can induce stronger anticancer immune response, and both in vitro and in vivo, mature YTHDF1-deficient DCs can induce stronger T cell activation than wild-type cells (57). Here, YTHDF1 is linked to melanoma.